ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1242

Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis
Abstract Number: 1243

Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry
Abstract Number: 1244

Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid Arthritis in Clinical Remission but Elevated Negative PROs: A Pragmatic Pilot Study
Abstract Number: 1245

Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study
Abstract Number: 1246

The Effect of Tocilizumab on miR-146a-5p and EMMPRIN/CD147 in Rheumatoid Arthritis Patients
Abstract Number: 1247

Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis
Abstract Number: 1248

Adjusted Analyses of the Benefits of Autoantibody Enrichment on Efficacy Outcomes in Early RA, from a Pooled Analysis of 4 Abatacept RCTs
Abstract Number: 1249

In Rheumatoid Arthritis, Inhibition of the Lactate Monocarboxylate Transporters-1, and -4 in Pathological Fibroblast-Like Synoviocytes Led to Decreased ChemokineProduction
Abstract Number: 1250

Abatacept and Other DMARDs Have Common Transcriptomic Effects on RA Synovial Tissue
Abstract Number: 1251

Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis
Abstract Number: 1252

Discontinuation of TNFi Treatment Among Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor-ɑ Inhibitor Therapies
Abstract Number: 1253

Acupuncture in Rheumatoid Arthritis Activity
Abstract Number: 1254

The Role of Regulatory T Cells (CD4+CD25+FOXP3) in Methotrexate Unresponsiveness in a Cohort of Naive Rheumatoid Arthritis Patients
Abstract Number: 1255

A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months
Abstract Number: 1256

Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].